Scott Peterson, MD
Family Medicine · Orem, UTNPI 1427008812
Payments from drug & device makers
Across 343 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$861
- AbbVie$777
- Lilly USA, LLC$539
- AstraZeneca$485
- Merck$425
- Amgen$376
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,648100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 41 | $861 |
| AbbVie(2 entities) | 51 | $777 |
| Lilly USA, LLC | 36 | $539 |
| AstraZeneca | 31 | $485 |
| Merck | 26 | $425 |
| Amgen | 26 | $376 |
| Astellas Pharma US Inc | 20 | $353 |
| Novo Nordisk | 20 | $320 |
| GSK | 13 | $206 |
| Pfizer | 13 | $204 |
| Johnson & Johnson | 10 | $154 |
| Amarin Pharma, Inc. | 8 | $131 |
| Abbott | 5 | $104 |
| Organon | 4 | $72 |
| Bayer | 4 | $66 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Sanofi Pasteur Inc. | 2 | $39 |
| Ultragenyx Pharmaceutical Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Cranial Technologies, Inc | 2 | $35 |
| Eisai Inc. | 3 | $34 |
| Supernus Pharmaceuticals, Inc. | 1 | $32 |
| Globus Medical | 1 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Bausch Health US, LLC | 2 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Mayne Pharma Commercial LLC | 2 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $11 |
How this compares
$5,655 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 95 | $130,086 |
| EliquisApixaban | 61 | $75,546 |
| OzempicSemaglutide | 33 | $63,248 |
| MyrbetriqMirabegron | 48 | $47,456 |
| TrulicityDulaglutide | 29 | $41,404 |
| FarxigaDapagliflozin Propanediol | 35 | $41,052 |
| JanuviaSitagliptin Phosphate | 28 | $25,055 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $6,576 |
| Atorvastatin Calcium | 436 | $6,456 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,195 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $4,356 |
| Levothyroxine Sodium | 292 | $4,069 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $3,309 |
| Omeprazole | 156 | $3,174 |
| Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide | 64 | $3,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $861 | $136,662106 claims |
| PfizerEliquis | $204 | $75,54661 claims |
| Novo NordiskOzempic | $320 | $63,24833 claims |
| Astellas Pharma US IncMyrbetriq | $353 | $47,45648 claims |
| Lilly USA, LLCTrulicity | $539 | $41,40429 claims |
| AstraZenecaFarxiga | $485 | $41,05235 claims |
| MerckJanuvia, Asmanex | $425 | $27,09646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 928 family medicine providers in Utah.
Other family medicine in Orem
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
- Katie JulienSouth Jordan$7.1M
- Scott EricksonBountiful$3.7M
- John RichardsSouth Jordan$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.